Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial

Authors:

Abstract
Background. No prospective, randomized, double-blind trials of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers have previously been reported in adults or children with proteinuria secondary to Alport syndrome. Methods. This 12-week, double-blind multinational study investigated the effects of losartan 0.7–1.4 mg/kg/day compared with placebo (normotensive patients) or amlodipine 0.1–0.2 mg/kg/day up to 5 mg/day (hypertensive patients) on proteinuria [early morning-void urinary protein/creatinine ratio (UPr/Cr), baseline ≥34 mg/mmol] in 30 children of up to 17 years of age with Alport syndrome. Results. Twelve weeks of treatment with losartan significantly reduced proteinuria compared with placebo/amlodipine: losartan −14.7 mg/mmol (interquartile range −49.7 to −5.7 mg/mmol) or 31.6% reduction using a mixed model approach versus placebo/amlodipine 2.3 mg/mmol (−26.0 to 18.1 mg/mmol), P = 0.01 or 2.3% increase using a mixed model approach. Adverse event incidence was low and comparable between losartan and placebo/amlodipine groups. Conclusions. Losartan significantly lowered proteinuria and was well tolerated after 12 weeks of treatment in children aged 1–17 years with proteinuria secondary to Alport syndrome with or without hypertension, a population that has not previously been rigorously studied.

This publication has 18 references indexed in Scilit: